RedHill Biopharma (RDHL) announced plans to advance its groundbreaking late-stage program for Crohn’s disease, or CD, with initiation of an ...

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® ...

Rosalinda, from Mananara in northern Madagascar, received free surgery on Monday, March 10th on board the Africa Mercy® ...

Measles is unlike other childhood viruses. In severe cases, it can cause pneumonia. About 1 in 1,000 patients develops encephalitis.

Combined company expected to trade on Nasdaq under “KLRS” after closingPALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 ...

Kalaris Therapeutics, Inc. ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization ...

Title: Initial Experience from the INSPIRE DUCHENNE Phase I/II Study of SGT-003 Microdystrophin Gene Therapy for Duchenne ...

Q4 2024 Earnings Call Transcript March 11, 2025 Zevra Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0 ...

The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.